Brain Scans Show How Ketamine Lifts Treatment-Resistant Depression
What a new Molecular Psychiatry study shows about AMPA receptors, plasticity, and personalized ketamine therapy
A March 2026 study published in Molecular Psychiatry uses PET brain imaging to offer a clearer look at how ketamine may rapidly improve symptoms in treatment-resistant deprsession.
With the imaging, researchers were able to observe changes in AMPA receptors, a type of glutamate receptor involved in communication between brain cells and synaptic plasticity. In basic terms, AMPA receptors help the brain update, adapt, and form new patterns (what we commonly refer to as neuroplasticity).
Treatment-resistant depression can feel like being trapped in the same painful loop: the same thoughts, the same emotional responses, the same inability to feel relief, even after multiple medication trials.
This study suggests that ketamine may help interrupt that rigidity by changing AMPA receptor activity in specific brain regions involved in mood, motivation, reward, and perception, allowing the brain to form new patterns that “break the loop.”
This is the first study to directly image AMPA receptor changes after ketamine treatment in living patients with treatment-resistant depression.
Previous research had already suggested that AMPA receptors play an important role in ketamine’s antidepressant effects, but most of that evidence came from animal studies, cell studies, or indirect measures.
The research team used a PET tracer called [¹¹C]K-2, which allows AMPA receptors to be visualized in the living human brain.
They compared patients with treatment-resistant depression to healthy participants, then followed AMPA receptor changes in patients who received ketamine in a controlled clinical trial setting.
The ketamine protocol used in the study was IV ketamine at 0.5 mg/kg over 40 minutes, given twice weekly for two weeks. Patients were assessed clinically and with PET imaging before and after treatment.
This allowed the researchers to ask two questions:
Do people with treatment-resistant depression show different AMPA receptor patterns than healthy participants?
When ketamine improves depressive symptoms, are those improvements connected to measurable AMPA receptor changes?
The answer to both appears to be yes.
Source: Nature
Ketamine appeared to rebalance AMPA activity rather than simply increase it everywhere.
One of the most important findings is that ketamine did not produce one uniform brain-wide effect.
Instead, the changes were regional.
In patients whose depressive symptoms improved, researchers saw increased AMPA receptor density in areas including the precuneus, superior parietal cortex, middle cingulate cortex, and occipital lobe. These regions are involved in functions such as working memory, reward anticipation, perception, and internal processing.
At the same time, improvement was also associated with decreased AMPA receptor density in other areas, including the habenula, putamen, pallidum, cerebellum, and thalamus/parahippocampal regions.
| AMPA receptor density increased | AMPA receptor density decreased |
|---|---|
| Precuneus | Habenula |
| Superior parietal cortex | Putamen |
| Occipital lobe | Pallidum |
| Middle cingulate cortex | Cerebellum |
| Left frontal lobe | Thalamus / parahippocampal regions |
Several of these areas are involved in reward, motivation, aversion, and depressive circuitry. The habenula, in particular, has been studied in relation to disappointment, negative prediction, and aversive signaling.
In plain English, ketamine did not appear to work by simply “turning up” AMPA receptors everywhere. It appeared to help rebalance AMPA receptor patterns in specific circuits — increasing density where patients with treatment-resistant depression showed lower AMPA density, and decreasing density in regions where AMPA density appeared elevated.
That is part of what makes this study notable. It suggests that ketamine’s antidepressant effect may be tied to targeted changes in brain systems involved in mood, motivation, reward, and perception.
The AMPA changes were linked to improvement in depressive symptoms.
The researchers found that changes in AMPA receptor density were associated with improvement in depression scores.
Some of the regions involved are related to reward, motivation, emotional processing, working memory, and perception. The study also found AMPA-related changes in areas such as the precuneus, cingulate cortex, basal ganglia, cerebellum, occipital cortex, and reward-related circuitry involving the habenula.
This is clinically meaningful because it connects what patients often report: a rapid shift in mood, perspective, flexibility, or emotional access (with measurable changes in the brain).
This does not mean ketamine is a cure, and it does not mean every patient will respond. But it does add to the evidence that ketamine’s antidepressant effects are not simply psychological, sedating, or placebo-based. They appear to involve real changes in brain systems tied to plasticity, that we can now see on brain imaging.
Why this study is relevant for ketamine treatment:
For clinicians, this study adds human imaging evidence to a model that has been building for years: ketamine’s antidepressant effects are closely tied to glutamate signaling, AMPA receptor activity, and synaptic plasticity.
For patients who feel uncertain about ketamine, the value of this study is that it shows measurable brain changes associated with symptom improvement. The benefit patients report after ketamine treatment is not simply about “feeling different” during the session. In this study, improvement was linked to changes in brain receptors involved in mood, motivation, reward, and the brain’s ability to form new patterns.
Depression is not simply a “chemical imbalance.” It can involve patterns in brain networks that become rigid, less adaptive, and harder to shift. Ketamine appears to work, at least in part, by creating a temporary window of increased plasticity, a period when the brain may be more able to update old patterns.
That is one reason the treatment setting (before/preparation and after/integration) matters.
We cannot simply administer ketamine and hope the brain changes on its own. We must use the treatment window carefully, with the right medical oversight, therapeutic support, and integration so that new patterns have a better chance of taking hold.
AMPA imaging may eventually help personalize depression care.
A promising angle of this study is its potential future use as a biomarker.
Because AMPA receptor patterns were linked with treatment response, AMPA-specific PET imaging may one day help researchers predict who is more likely to benefit from ketamine or related treatments.
That said, this is not something most clinics can use right now. PET imaging is expensive, technically complex, and still primarily a research tool.
The larger point is that studies like this move the field toward more personalized depression care. Instead of relying only on trial and error, future treatment decisions may be guided by measurable brain-based markers.
What patients should understand:
If you are considering ketamine treatment for depression, this study does not mean ketamine is right for everyone.
It does mean that ketamine is being studied as a targeted medical intervention with measurable effects on brain systems involved in mood and plasticity.
When used appropriately, it may help the brain become more flexible, and that flexibility can create an opportunity for meaningful therapeutic change.
At NeuroPain Health, we see ketamine treatment as one part of a larger care model. The medication may open a window. What happens inside that window — therapy, integration, nervous system regulation, and ongoing support — is what helps determine whether that change can become more durable.
Curious about how ketamine treatment could help you? Contact our office today.